Several major biotech companies like Biogen (BIIB – Analyst Report), AbbVie (ABBV – Analyst Report), Celgene and Gilead reported second quarter results over the last five trading days. Biogen has been grabbing headlines for the wrong reasons – although the company’s earnings were better-than-expected, revenues missed expectations.With the company saying that it is cutting its outlook based on revised expectations […]
Avalanche Biotech (NASDAQ:AAVL)Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were mediocre at best. In addition if […]
An FDA advisory panel voted in favor of approving Regeneron (REGN – Analyst Report) and partner Sanofi’s PCSK9 inhibitor, Praluent. A few deals were also signed over the last few days by companies like Vertex (VRTX – Analyst Report), Celgene (CELG – Analyst Report) and Seattle Genetics (SGEN – Analyst Report).Recap of the Week’s Most Important Stories1. Regeneron and Sanofi […]
By Ben LevisohnBarclays’ Geoff Meacham and Jonathan Eckard are feeling good about biotech stocks like Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) heading into the summer. They explain why:
Associated Press
[The] Nasdaq Biotech Index index has outperformed the broader market eight out of 10 times over the summer period (Memorial Day to Labor Day) and in 2Q/3Q, there are a number of meaningful […]
Last summer, Federal Reserve Chair Janet Yellen said valuations in certain corners of the stock market like biotech were getting “substantially stretched,” and traders have gotten a good laugh at her warning ever since as the stocks resumed their winning ways and raced higher. But given the recent battering of the biotech stocks, the caution recommended by the central bank […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
A doubling of Gilead Sciences ‘ sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences’ sales growth set to slow this year, investors may find that these three top biotech stocks prove to be a better bet in 2015.Source: Biogen Idec: Gilead Sciences’ slowing sales growth this year […]
Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big biotechs […]
Source: Celgene CorporationThe biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn’t necessarily mean that they’ll rally next year, too.Biotech stocks can move significantly higher or lower in any given year due to investor’s reaction to data from ongoing drug trials, […]
LONDON, November 24, 2014 /PRNewswire/ –Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 21, 2014, the NASDAQ Composite ended at 4,712.97, […]
